Financial News · Live Terminal

Page 32 of 413

UBS Downgrades Crinetics Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $85 From $55

Crinetics Pharmaceuticals (CRNX) has an average rating of hold and mean price target of $85.50, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

Financial News · Live Terminal

UBS Downgrades Crinetics Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $85 From $55

Morgan Stanley Downgrades Laureate Education to Underweight From Equalweight, Adjusts PT to $34.50 From $36.50

UBS Initiates Bausch + Lomb at Buy With CA$29.64 Price Target

UBS Initiates Alphatec Holdings at Buy With $15 Price Target

Wells Fargo Downgrades Levi Strauss & Co. to Equalweight From Overweight, Price Target is $25

Stephens Downgrades Eastern Bankshares to Equalweight From Overweight, Price Target is $24

Barclays Downgrades Progyny to Equalweight From Overweight, Adjusts Price Target to $34 From $27

TD Cowen Downgrades RXO to Sell From Hold, Adjusts Price Target to $19 From $24

Wedbush Initiates Benitec Biopharma at Outperform With $16 Price Target

BMO Capital Downgrades Selective Insurance to Market Perform From Outperform, Price Target is $97

Canaccord Genuity Initiates Tenax Therapeutics at Buy With $35 Price Target

Piper Sandler Initiates Kodiak Gas Services at Overweight

UBS Initiates Cooper Companies at Neutral With $75 Price Target

UBS Upgrades BFI Finance Indonesia to Neutral from Sell; Price Target is IDR835

Phillip Securities Starts Izumi at Buy with 1,280 Yen Price Target

MIDF Amanah Downgrades QL Resources to Neutral from Buy; Price Target is MYR4.11

Tokai Tokyo Downgrades Idom to Neutral from Outperform; Price Target is 1,420 Yen

Hong Leong Starts Malayan Flour Mills at Buy with MYR0.93 Price Target

PT Verdhana Sekuritas Indonesia Starts Dharma Satya Nusantara at Buy with IDR2,100 Price Target

Jefferies Downgrades Clorox to Hold From Buy, Adjusts Price Target to $98 From $125

UBS Downgrades Crinetics Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $85 From $55

Morgan Stanley Downgrades Laureate Education to Underweight From Equalweight, Adjusts PT to $34.50 From $36.50

UBS Initiates Bausch + Lomb at Buy With CA$29.64 Price Target

UBS Initiates Alphatec Holdings at Buy With $15 Price Target

Wells Fargo Downgrades Levi Strauss & Co. to Equalweight From Overweight, Price Target is $25

Stephens Downgrades Eastern Bankshares to Equalweight From Overweight, Price Target is $24

Barclays Downgrades Progyny to Equalweight From Overweight, Adjusts Price Target to $34 From $27

TD Cowen Downgrades RXO to Sell From Hold, Adjusts Price Target to $19 From $24

Wedbush Initiates Benitec Biopharma at Outperform With $16 Price Target

BMO Capital Downgrades Selective Insurance to Market Perform From Outperform, Price Target is $97

Canaccord Genuity Initiates Tenax Therapeutics at Buy With $35 Price Target

Piper Sandler Initiates Kodiak Gas Services at Overweight

UBS Initiates Cooper Companies at Neutral With $75 Price Target

UBS Upgrades BFI Finance Indonesia to Neutral from Sell; Price Target is IDR835

Phillip Securities Starts Izumi at Buy with 1,280 Yen Price Target

MIDF Amanah Downgrades QL Resources to Neutral from Buy; Price Target is MYR4.11

Tokai Tokyo Downgrades Idom to Neutral from Outperform; Price Target is 1,420 Yen

Hong Leong Starts Malayan Flour Mills at Buy with MYR0.93 Price Target

PT Verdhana Sekuritas Indonesia Starts Dharma Satya Nusantara at Buy with IDR2,100 Price Target

Jefferies Downgrades Clorox to Hold From Buy, Adjusts Price Target to $98 From $125